Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00108732 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00108732: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00108732 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00108732, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Androgens can cause the growth of prostate cancer cells. Drugs, such as bicalutamide and goserelin, may stop the adrenal glands from making androgens in patients whose tumor cells continue to grow. Giving vaccine therapy together with GM-CSF and, when needed, androgen ablation may be a more effective treatment for prostate cancer. This phase II trial is studying how well giving vaccine therapy together with GM-CSF works in treating patients with prostate cancer that progressed after surgery and/or radiation therapy.
Interventions
- DRUG Bicalutamide
- DRUG Goserelin Acetate
- BIOLOGICAL Sargramostim
- BIOLOGICAL Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
- BIOLOGICAL Recombinant Vaccinia-TRICOM Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-02 |
| Est. Completion | 2010-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00108732
The ClinicalTrials.gov registry entry for NCT00108732 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bicalutamide is the first listed.
NCT00108732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00108732 about?
NCT00108732 is a clinical study titled "A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer". Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells. Biological therapies, such as GM-CSF, may stimulate the immune system in different ways and stop tumor cells from growing. Androgens can cause the growth of prostate cancer cells. Drugs...
What is the current status of trial NCT00108732?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2006-02. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00108732?
The interventions under investigation include: Bicalutamide (DRUG), Goserelin Acetate (DRUG), Sargramostim (BIOLOGICAL), Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine (BIOLOGICAL), Recombinant Vaccinia-TRICOM Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00108732?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.